| 产品编号 | bs-102969P |
| 英文名称 | Recombinant Human ILF3 Protein, N-His |
| 中文名称 | |
| 别 名 | ILF3; MPHOSPH4; DRBP76; TCP80; DRBF; Translational control protein 80; M-phase phosphoprotein 4; Nuclear factor associated with dsRNA; NF90; NFAR; MPP4; NF-AT-90; Double-stranded RNA-binding protein 76; Interleukin enhancer-binding factor 3; Nuclear factor of activated T-cells 90 kDa |
| 克 隆 号 | |
| 理论分子量 | 24.49 kDa |
| 性 状 | Lyophilized |
| 纯 度 | >90% as determined by SDS-PAGE. |
| 缓 冲 液 | Lyophilized from a solution in TBS pH 8.0, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol. |
| 保存条件 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 产品介绍 |
This gene encodes a double-stranded RNA (dsRNA) binding protein that complexes with other proteins, dsRNAs, small noncoding RNAs, and mRNAs to regulate gene expression and stabilize mRNAs. This protein was first discovered to be a subunit of the nuclear factor of activated T-cells (NFAT); a transcription factor required for T-cell expression of interleukin 2. NFAT is a heterodimer of 45 kDa and 90 kDa proteins, the larger of which is the product of this gene. These proteins have been shown to affect the redistribution of nuclear mRNA to the cytoplasm. Knockdown of NF45 or NF90 protein retards cell growth; possibly by inhibition of mRNA stabilization. In contrast, an isoform (NF110) of this gene that is predominantly restricted to the nucleus has only minor effects on cell growth when its levels are reduced. Alternative splicing results in multiple transcript variants encoding distinct isoforms.[provided by RefSeq, Nov 2008] SWISS: Q12906 Gene ID: 3609 |
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
